Context Therapeutics (NASDAQ:CNTX) Earns Outperform Rating from Analysts at JMP Securities

Equities research analysts at JMP Securities began coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research note issued to investors on Wednesday, MarketBeat reports. The firm set an “outperform” rating and a $4.00 price target on the stock. JMP Securities’ price objective points to a potential upside of 266.97% from the company’s previous close.

A number of other brokerages have also recently weighed in on CNTX. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Context Therapeutics in a research report on Monday, September 23rd. D. Boral Capital started coverage on shares of Context Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $9.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $6.33.

Context Therapeutics Stock Performance

CNTX opened at $1.09 on Wednesday. The business’s 50 day moving average price is $1.56 and its 200 day moving average price is $1.95. The stock has a market capitalization of $81.75 million, a PE ratio of -1.20 and a beta of 2.10. Context Therapeutics has a one year low of $0.89 and a one year high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). As a group, equities research analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

Hedge funds have recently made changes to their positions in the business. Y Intercept Hong Kong Ltd acquired a new stake in Context Therapeutics during the 3rd quarter worth approximately $89,000. Renaissance Technologies LLC raised its stake in shares of Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares in the last quarter. State Street Corp boosted its holdings in Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after purchasing an additional 19,800 shares during the period. Affinity Asset Advisors LLC boosted its holdings in Context Therapeutics by 392.4% in the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,290,323 shares during the period. Finally, Franklin Resources Inc. acquired a new position in Context Therapeutics during the 3rd quarter worth $3,689,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.